The recent release of new SEC filings from pharmaceutical companies has shed light on the cost-cutting measures taken by influential figures such as Donald Trump and Elon Musk. These actions are allegedly aimed at reducing expenses and increasing profits, but may have a more sinister effect - slowing down drug research and delaying FDA approvals.Pharmaceutical companies face significant financial pressures, and it is understandable that they would seek ways to reduce costs. However, this can have far-reaching consequences for public health. Delays in bringing new treatments and medications to market can lead to suffering and even loss of life.Regulatory agencies must take notice of these practices and ensure that pharmaceutical companies operate within a framework that prioritizes patient safety and well-being over financial gain. The public has a right to know about these practices and demand transparency from regulatory bodies.